A non-covalent peptide-based strategy for siRNA delivery.
The major obstacle to clinical development of siRNAs (short interfering RNAs), like for most of the nucleic-acid-based strategies, is their poor cellular uptake and bioavailability. Although several viral and non-viral strategies have been proposed to improve siRNA delivery, their applications in vivo remain a major challenge. We have developed a new strategy, based on a short amphipathic peptide, MPG, that is able to form stable nanoparticles with siRNA. MPG-based particles enter the cell independently of the endosomal pathway and can efficiently deliver siRNA in a fully biologically active form into a variety of cell lines and in vivo. This short review will discuss the mechanism and the potency of the MPG strategy for siRNA delivery both in vitro and in vivo.
Crombez
L
L
Centre de Recherches de Biochimie Macromoléculaire, CRBM-CNRS, Department of Molecular Biophysics and Therapeutics, 1919 Route de Mende, 34293 Montpellier, France.
Charnet
A
A
Morris
M C
MC
Aldrian-Herrada
G
G
Heitz
F
F
Divita
G
G
D000818:Animals; D001672:Biocompatible Materials / Q000737:chemistry; D002460:Cell Line; D016503:Drug Delivery Systems; D020868:Gene Silencing; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D051379:Mice; D008954:Models, Biological; D053758:Nanoparticles / Q000737:chemistry; D036103:Nanotechnology / Q000379:methods; D010455:Peptides / Q000737:chemistry*; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000378:metabolism
D001672:Biocompatible Materials; D010455:Peptides; D034741:RNA, Small Interfering